Mark Bloomfield

Back small companies to deliver new medicines

Pharmaceutical R&D functions at its best in small, agile and innovative SMEs. Replacing state subsidies and grant funding for research with start-up and development capital, would bring productivity improvements, says Mark Bloomfield, CEO of French biotech Polyplus Transfection

09 Jul 2014

News

Subscribe to Mark Bloomfield

Get our free Science|Business newsletters

Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.

Find out more about the Science|Business Network

Network icon A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.

Why join?

Become a member

Jobs

Eureka is seeking a Process Expert Evaluation and Ethics

News
- Funding Newswire
- The Widening
- R&D Policy
- Health
- Energy
- Climate
- Digital
- Defence
Funding Newswire
- Why subscribe?
Reports
Events
The Network
Communications Services
About Us
- Contact
- Team
- Privacy
- Careers